What Analysts Recommend for Sage Therapeutics
Sage Therapeutics’ valuation
Sage Therapeutics (SAGE) is a clinical-research-based biopharmaceutical company focused on developing drugs for life-threatening central nervous system disorders like postpartum depression, Parkinson’s disease, and others.
Interested in SAGE? Don't miss the next report.
Receive e-mail alerts for new research on SAGE
The above chart shows analysts’ recommendations for Sage Therapeutics over the last 12 months. The company hasn’t generated any revenues from product sales since inception nor does the company expect to generate any revenues from product sales in the near future.
Sage Therapeutics’ stock price has risen nearly 54.5% over the last 12 months, while the analysts estimate the stock has a potential to return 30.3% over the next 12 months. Wall Street analysts’ recommendations show a 12-month targeted price of $83.69 per share as compared to the last price of $70.37 per share as of September 13, 2017. In comparison, 13 analysts are tracking Merck’s stock. Of these, 11 analysts recommend a “buy,” while two analysts recommend a “hold.” The consensus rating on Sage Therapeutics stock is 1.7, which represents a buy for both momentum investors and long-term investors.
Sage Therapeutics’ stock price has risen nearly 54.5% over the last 12 months, while the analysts estimate the stock has a potential to return 30.3% over the next 12 months. Wall Street analysts estimate a net loss of $75.3 million during 3Q17 and a net loss of $79.1 million during 4Q17. No revenues are expected from product sales in the next few quarters.
To divest company-specific risks, investors can consider ETFs like the Vanguard Healthcare ETF (VHT), which holds 0.1% of its total assets in Sage Therapeutics. VHT also holds 3.0% in Celgene (CELG), 1.8% in Biogen (BIIB), and 3.1% in AbbVie (ABBV).